Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo, Clear all

Conditions: Autism Spectrum Disorders
Interventions: Sham OMM, Osteopathic Manual Medicine (Body Therapy); Other
Lead sponsor: New York Institute of Technology; Other
Eligibility: 3 Years to 11 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Central Islip, New York • Old Westbury, New York

Conditions: Obesity
Interventions: VI-0521, topiramate, phentermine; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Durham, North Carolina • Philadelphia, Pennsylvania

Conditions: Hunger
Interventions: psyllium fiber 6.8g, placebo; Dietary Supplement
Lead sponsor: Procter and Gamble; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Secondary Hypogonadism
Interventions: Androxal 12.5 mg/25 mg, Placebo Capsules, AndroGel 1.62%, Placebo Gel; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 9
States / cities: Birmingham, Alabama • Mobile, Alabama • Evanston, Illinois + 6 more

Conditions: Atrial Fibrillation
Interventions: Omega -3 fatty acids, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 1,516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Wild blueberry containing foods, Placebo containing foods; Dietary Supplement
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 11 Years to 12 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Inflammation, Rheumatoid Arthritis
Interventions: NNC0109-0012, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 92
States / cities: Huntsville, Alabama • Tuscaloosa, Alabama • Mesa, Arizona + 81 more

Conditions: Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions: diindolylmethane, placebo; Dietary Supplement
Lead sponsor: University of Arizona; Other
Eligibility: 19 Years and older · Female only
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: D008593
Interventions: Shatavari Root Extract, oral capsule; Dietary Supplement
Lead sponsor: Jacksonville University; Other
Eligibility: 40 Years to 60 Years · Female only
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Renal Insufficiency, Chronic Hypertension
Interventions: Spironolactone, Chlorthalidone, Placebo; Drug
Lead sponsor: Indiana Institute for Medical Research; Other
Eligibility: 19 Years to 110 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Behavioral Pharmacology of Cannabis
Interventions: Oral Delta-8-THC Cannabis, Oral Delta-9-THC Cannabis, Oral Placebo, Vaporized Delta-8-THC Cannabis, Vaporized Delta-9-THC Cannabis, Vaporized Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Low Back Pain
Interventions: Erchonia MLS, Placebo Laser; Device
Lead sponsor: Erchonia Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Chandler, Arizona • Scottsdale, Arizona

Conditions: Hypertension
Interventions: Orforglipron, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 974 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 29
States / cities: Phoenix, Arizona • Covina, California • Northridge, California + 24 more

Conditions: Chronic Kidney Disease
Interventions: Calcium acetate, Lanthanum Carbonate, Sevelamer Carbonate, Placebo; Drug
Lead sponsor: Denver Nephrologists, P.C.; Other
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Psoriatic Arthritis (PsA)
Interventions: Deucravacitinib, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy
Interventions: PF-05230907, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Stress Response, Mental Stress, Multitasking Behavior and Multitasking Ability, Physiological Stress, Cognitive Symptoms, Motor Activity
Interventions: Cranberry juice, Placebo juice; Other
Lead sponsor: University of Florida; Other
Eligibility: 30 Years to 55 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Calciphylaxis
Interventions: EPN-701 (Oral), Placebo (Normal Saline); Drug
Lead sponsor: Sagar U. Nigwekar, MD, MMSc; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Coronary Artery Disease, Pain, Peripheral Nervous System Diseases, Polyneuropathy
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Houma, Louisiana

Conditions: Nausea and Vomiting, Chemotherapy-Induced
Interventions: Casopitant, Dexamethasone, Placebo, Ondansetron; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 710 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 23
States / cities: Hot Springs, Arkansas • Corona, California • Fountain Valley, California + 19 more

Conditions: Pain
Interventions: Celecoxib, Sugar Pill; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Essential Tremor
Interventions: ST101, Placebo; Drug
Lead sponsor: Sonexa Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Aneurysmal Subarachnoid Hemorrhage
Interventions: Tirofiban, Placebo; Drug
Lead sponsor: Dr David Hasan, M.D.; Other
Eligibility: 18 Years to 85 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 2
States / cities: Durham, North Carolina • Houston, Texas

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg), Aclidinium bromide 400 μg (AB 400 μg), Formoterol fumarate 12 μg (FF 12 μg), Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg, Tiotropium 18 μg (TIO 18 μg), Placebo to TIO 18 μg; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 130 Years
Enrollment: 1,595 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 85
States / cities: Gulf Shores, Alabama • Phoenix, Arizona • Tucson, Arizona + 74 more

Search by objective public record fields.

Osteopathic Manual Medicine Treatment in Autism

A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults

Study of Psyllium 6.8 g Versus Placebo on Satiety in Healthy Volunteers

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation

The Blueberry Study

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Diindolylmethane in Treating Patients With Breast Cancer

Effect of a Cepham Supplement on Hot Flashes and Menopausal Symptoms in Postmenopausal Women

Spironolactone in CKD Enabled by Chlorthalidone: PILOT

Comparative Pharmacokinetic and Pharmacodynamic Effects of Delta-8 and Delta-9 THC

Study of Low Level Laser Therapy to Treat Low Back Pain

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD

Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease

Single Dose Study of PF-05230907 in Healthy Japanese Subjects

Cranberry Polyphenols and Stress Resilience During Multitasking in Healthy Adults

Study of EPN-701 for the Treatment of Calciphylaxis

Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy

A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.

Effectiveness of Celecoxib After Surgical Sperm Retrieval

A Pilot Efficacy and Safety Study of ST101 in Essential Tremor

Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2)

AMPLIFY - D6571C00001 Duaklir USA Phase III Study